Humana's Balanced Market Outlook and Cost Control Recovery Justify Buy Rating
Humana Analyst Ratings
Oppenheimer Maintains Humana(HUM.US) With Buy Rating, Raises Target Price to $400
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ) and Humana (HUM)
Truist Financial Sticks to Their Hold Rating for Humana (HUM)
Truist Financial Maintains Humana(HUM.US) With Hold Rating
Humana Inc. (HUM) Outshines Expectations With Strong Q2 Performance and Positive Outlook: A 'Buy' Rating Justified
Barclays Maintains Humana(HUM.US) With Hold Rating, Cuts Target Price to $364
Humana (HUM) Gets a Hold From Barclays
HSBC Adjusts Price Target on AbbVie to $215 From $185
Argus Adjusts Price Target on Boston Scientific to $90 From $95
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Evercore Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $192
BNP Paribas Exane Adjusts Price Target on AbbVie to $193 From $172
Evercore ISI Sticks to Its Buy Rating for AbbVie (ABBV)
TD Cowen Maintains Humana(HUM.US) With Buy Rating, Maintains Target Price $407
Analysts' Top Healthcare Picks: Edwards Lifesciences (EW), AbbVie (ABBV)
Daiwa Securities Adjusts Price Target on Boston Scientific to $83 From $81, Maintains Buy Rating
Eli Lilly & Co Faces European Market Challenges; Analyst Maintains Hold Rating
Analysts' Opinions Are Mixed on These Healthcare Stocks: Regeneron (REGN), AptarGroup (ATR) and AbbVie (ABBV)